<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01523314</url>
  </required_header>
  <id_info>
    <org_study_id>DECEDE</org_study_id>
    <nct_id>NCT01523314</nct_id>
  </id_info>
  <brief_title>Topical Dexamethasone - Cyclodextrin Microparticle Eye Drops for Diabetic Macular Edema</brief_title>
  <acronym>DECEDE</acronym>
  <official_title>Topical Dexamethasone - Cyclodextrin Microparticle Eye Drops for Diabetic Macular Edema</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>King Saud University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>King Saud University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The research group has developed new ocular drug delivery technology based on cyclodextrin
      nanoparticles (NP). The investigators plan to develop and test this technology to help treat
      diabetic macular edema (DME).

      An important step in research was the invention of cyclodextrin nanoparticles, which has just
      received a US patent. The investigators pre-clinical and clinical work has demonstrated the
      investigators eye drop suspension with cyclodextrin nano-particles to be superior to
      conventional eye drops. They increase drug absorbance into the eye and decrease systematic
      distribution of the drug, hence reducing side effects. Cyclodextrin nanoparticle eye drops
      deliver drugs to the posterior part of the eye, thus solving one of the biggest obstacles in
      ocular pharmacology.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>March 2012</start_date>
  <completion_date type="Anticipated">February 2013</completion_date>
  <primary_completion_date type="Anticipated">August 2012</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Best Corrected Visual Acuity on ETDRS chart</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Intraocular pressure (IOP)</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Diabetic Macular Edema</condition>
  <arm_group>
    <arm_group_label>dexamethasone - Cyclodextrin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Avastin/Laser</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dexamethasone - Cyclodextrin eye drops</intervention_name>
    <description>The study eye will receive the dexamethasone NP eye drops 3 times a day for 3 months. The subject will be handed an eye drop bottle at each monthly visit for self administration of the eye drops. Each eye drop container is to be marked with a date when first opened and discarded after 1 week (unless it contains a preservative).</description>
    <arm_group_label>dexamethasone - Cyclodextrin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>intravitreal Avastin injection +/- macular laser</intervention_name>
    <description>The study eye will receive standard laser and intravitreal injections of Avastin for 3 months. Complete eye examination will be performed prior to drug administration.</description>
    <arm_group_label>Avastin/Laser</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type 2 diabetes mellitus

          -  Pseudophakic in study eye, i.e. with IOL (intra ocular lens) after cataract surgery

          -  Diabetic macular edema with central macular thickness over 300 µm on OCT in study eye.
             If both eyes have DME, then the treatment will be applied to the eye with thicker
             central macula on OCT.

          -  Age 18 years or older

        Exclusion Criteria:

          -  Glaucoma or use of any glaucoma medication

          -  Known steroid IOP response

          -  Any infectious eye disease

          -  Treatment for DME within 6 months, such as laser treatment, intravitreal or subtenon
             injections of steroids, intravitreal injections of anti vascular endothelelial growth
             factor medication.

          -  Any eye surgery within 3 months or other eye conditions e.g. corneal disorders, ocular
             hypotony and retinal detachments.

          -  Crystalline lens present in study eye

          -  Known allergy to cyclodextrins, dexamethasone, ranibizumab or any of the components of
             the study medications
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>College of Medicine, King Saud University</name>
      <address>
        <city>Riyadh</city>
        <zip>11411</zip>
        <country>Saudi Arabia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ahmed A Abu El-Asrar, MD, PhD</last_name>
      <phone>0096614786100</phone>
      <phone_ext>1430</phone_ext>
      <email>abuasrar@KSU.EDU.SA</email>
    </contact>
    <contact_backup>
      <last_name>Marwan A Abouammoh, MD</last_name>
      <phone>00966505476426</phone>
      <email>dr.abouammoh@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Einar Stefánsson, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Phatsawee Jansook, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Thorsteinn Loftsson, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Saudi Arabia</country>
  </location_countries>
  <verification_date>January 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 28, 2012</study_first_submitted>
  <study_first_submitted_qc>January 31, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 1, 2012</study_first_posted>
  <last_update_submitted>January 31, 2012</last_update_submitted>
  <last_update_submitted_qc>January 31, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 1, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>King Saud University</investigator_affiliation>
    <investigator_full_name>Ahmed Abu El-Asrar</investigator_full_name>
    <investigator_title>Professor, Consultant, Vitreoretinal/Uveitis division</investigator_title>
  </responsible_party>
  <keyword>diabetic macular edema</keyword>
  <keyword>intravitreal injection</keyword>
  <keyword>dexamethasone</keyword>
  <keyword>Cyclodextrin</keyword>
  <keyword>eye drops</keyword>
  <keyword>bevacizumab</keyword>
  <keyword>macular laser</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Edema</mesh_term>
    <mesh_term>Macular Edema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Tetrahydrozoline</mesh_term>
    <mesh_term>BB 1101</mesh_term>
    <mesh_term>Ophthalmic Solutions</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

